Monetary Management Group Inc. Purchases New Holdings in AstraZeneca PLC $AZNCF

Monetary Management Group Inc. purchased a new stake in AstraZeneca PLC (OTCMKTS:AZNCF) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 6,250 shares of the company’s stock, valued at approximately $1,097,000.

Other hedge funds have also made changes to their positions in the company. L & S Advisors Inc purchased a new stake in shares of AstraZeneca in the 4th quarter valued at approximately $14,863,000. Burling Wealth Partners LLC purchased a new stake in shares of AstraZeneca in the 4th quarter valued at approximately $4,532,000. Hendley & Co. Inc. purchased a new stake in shares of AstraZeneca in the 4th quarter valued at approximately $11,373,000. Saranac Partners Ltd purchased a new stake in shares of AstraZeneca in the 3rd quarter valued at approximately $876,000. Finally, Root Financial Partners LLC purchased a new stake in shares of AstraZeneca in the 4th quarter valued at approximately $622,000. Hedge funds and other institutional investors own 40.87% of the company’s stock.

AstraZeneca Stock Performance

AZNCF stock opened at $187.10 on Tuesday. AstraZeneca PLC has a 12-month low of $122.26 and a 12-month high of $195.00. The company has a 50 day moving average of $187.10 and a two-hundred day moving average of $185.82.

About AstraZeneca

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.